Dengue virus (DENV) affects not only peripheral immune cells but also hematopoietic progenitors in the bone marrow, particularly megakaryocytic precursors, which contribute to the thrombocytopenia characteristic of the disease. In this study, we evaluated the relationship between the differentiation status of the megakaryocytic lineage and its permissiveness and antiviral response to DENV. Our results demonstrate that the erythroid–megakaryocytic precursor (K562 cells) was more permissive to DENV infection than megakaryoblasts, as evidenced by immunofluorescence, flow cytometry, and quantification of viral particles. The antiviral response in K562 cells peaked at three days post-infection, with maximal expression of genes associated with the type I interferon (IFN-I) pathway. In vitro-induced differentiation of K562 cells reduced the initial susceptibility to DENV and enhanced the expression of Toll-like receptor 3 (TLR3) and the type I interferon receptor (IFNAR1), accelerating and intensifying IFN-β secretion, and increasing the expression of OAS2 and IRF3. Furthermore, pretreatment of K562 cells with recombinant IFN-β significantly reduced viral replication from the first day post-infection. Collectively, these findings demonstrate for the first time that the differentiation status of erythroid–megakaryocytic progenitor critically shapes their antiviral response and underscore the central role of IFN-β in the early restriction of DENV infection.
Dengue is the most prevalent arthropod-borne disease, causing 100-400 million infections annually. The clinical symptoms range from asymptomatic to severe, involving hemorrhage and organ failure. Severe dengue often occurs in secondary infections with different serotypes due to antibody-dependent enhancement (ADE). During the SARS-CoV-2 pandemic, cross-reactions between dengue and SARS-CoV-2 antibody tests have been reported, due to antibody cross-reactivity between the dengue envelope protein and SARS-CoV-2 S1-RBD protein. This study analyzed the serum proteome of dengue patients with and without SARS-CoV-2 IgG antibodies. We conducted a bottom-up label-free proteomic analysis of whole serum samples from healthy donors and dengue patients, with or without SARS-CoV-2 IgG antibodies. We identified 1,122 protein sequences, 296 of which were gene-associated. Gene ontology analysis revealed that dengue patients with both SARS-CoV-2 and dengue IgG antibodies had more genes involved in immune regulation, humoral response, blood coagulation, and platelet degranulation, which may increase severe dengue risk. Unique proteins linked to platelet activation, such as coagulation factor XIII B chain, thrombospondin, Antigen KI-67, bone marrow proteoglycan, and colorectal cancer mutant protein may explain thrombocytopenia mechanisms. Our results indicate that SARS-CoV-2 IgG antibodies in dengue infection cause differential protein expression compared with healthy donors or other groups.